Which has higher earnings and valuation, DLO or GDRX?

DLocal has higher revenue and earnings than GoodRx. DLocal is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DLocal $1.09B 3.07 $196.80M $0.63 18.10 GoodRx $796.85M 1.21 $30.44M $0.06 46.83

Is DLO or GDRX more profitable?

DLocal has a net margin of 15.85% compared to GoodRx's net margin of 2.61%. DLocal's return on equity of 41.22% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets DLocal 15.85% 41.22% 14.27% GoodRx 2.61% 7.90% 3.23%

Does the media refer more to DLO or GDRX?

In the previous week, DLocal had 1 more articles in the media than GoodRx. MarketBeat recorded 3 mentions for DLocal and 2 mentions for GoodRx. DLocal's average media sentiment score of 1.20 beat GoodRx's score of 0.63 indicating that DLocal is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DLocal 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, GDRX or SEZL?

Sezzle has lower revenue, but higher earnings than GoodRx. Sezzle is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.21 $30.44M $0.06 46.83 Sezzle $450.28M 8.45 $133.13M $4.21 26.89

Is GDRX or SEZL more profitable?

Sezzle has a net margin of 30.83% compared to GoodRx's net margin of 2.61%. Sezzle's return on equity of 87.46% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.61% 7.90% 3.23% Sezzle 30.83% 87.46% 36.29%

Does the media favor GDRX or SEZL?

In the previous week, Sezzle had 8 more articles in the media than GoodRx. MarketBeat recorded 10 mentions for Sezzle and 2 mentions for GoodRx. Sezzle's average media sentiment score of 0.85 beat GoodRx's score of 0.63 indicating that Sezzle is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sezzle 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GDRX or FOUR?

Shift4 Payments has higher revenue and earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than Shift4 Payments, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.21 $30.44M $0.06 46.83 Shift4 Payments $4.18B 0.76 $119M $0.84 47.82

Is GDRX or FOUR more profitable?

Shift4 Payments has a net margin of 2.63% compared to GoodRx's net margin of 2.61%. Shift4 Payments' return on equity of 33.55% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.61% 7.90% 3.23% Shift4 Payments 2.63% 33.55% 5.01%

Does the media refer more to GDRX or FOUR?

In the previous week, Shift4 Payments had 5 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for Shift4 Payments and 2 mentions for GoodRx. Shift4 Payments' average media sentiment score of 1.09 beat GoodRx's score of 0.63 indicating that Shift4 Payments is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shift4 Payments 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GDRX or LIF?

Life360 has lower revenue, but higher earnings than GoodRx. Life360 is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.21 $30.44M $0.06 46.83 Life360 $489.48M 7.66 $150.83M $1.73 26.74

Is GDRX or LIF more profitable?

Life360 has a net margin of 28.21% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat Life360's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.61% 7.90% 3.23% Life360 28.21% 6.80% 3.65%

Does the media prefer GDRX or LIF?

In the previous week, Life360 had 15 more articles in the media than GoodRx. MarketBeat recorded 17 mentions for Life360 and 2 mentions for GoodRx. GoodRx's average media sentiment score of 0.63 beat Life360's score of 0.48 indicating that GoodRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Life360 4 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, YY or GDRX?

JOYY has higher revenue and earnings than GoodRx. JOYY is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JOYY $2.24B 1.65 $301.82M -$3.10 N/A GoodRx $796.85M 1.21 $30.44M $0.06 46.83

Is YY or GDRX more profitable?

JOYY has a net margin of 9.02% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat JOYY's return on equity. Company Net Margins Return on Equity Return on Assets JOYY 9.02% 4.64% 2.96% GoodRx 2.61% 7.90% 3.23%

Does the media refer more to YY or GDRX?

In the previous week, GoodRx had 1 more articles in the media than JOYY. MarketBeat recorded 2 mentions for GoodRx and 1 mentions for JOYY. GoodRx's average media sentiment score of 0.63 beat JOYY's score of 0.53 indicating that GoodRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment JOYY 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GoodRx (GDRX) Competitors

$2.81 -0.14 (-4.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.78 -0.03 (-1.07%)

As of 07:58 PM Eastern

Compare

GDRX vs. DLO, SEZL, FOUR, LIF, and YY

Should you buy GoodRx stock or one of its competitors? MarketBeat compares GoodRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GoodRx include DLocal (DLO), Sezzle (SEZL), Shift4 Payments (FOUR), Life360 (LIF), and JOYY (YY). These companies are all part of the "business services" industry.

How does GoodRx compare to DLocal?

DLocal (NASDAQ:DLO) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

DLocal currently has a consensus target price of $16.63, suggesting a potential upside of 45.83%. GoodRx has a consensus target price of $3.81, suggesting a potential upside of 35.68%. Given DLocal's stronger consensus rating and higher probable upside, equities analysts clearly believe DLocal is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DLocal	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

DLocal has a net margin of 15.85% compared to GoodRx's net margin of 2.61%. DLocal's return on equity of 41.22% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DLocal	15.85%	41.22%	14.27%
GoodRx	2.61%	7.90%	3.23%

DLocal has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

90.1% of DLocal shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 45.4% of DLocal shares are owned by insiders. Comparatively, 5.9% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

DLocal has higher revenue and earnings than GoodRx. DLocal is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DLocal	$1.09B	3.07	$196.80M	$0.63	18.10
GoodRx	$796.85M	1.21	$30.44M	$0.06	46.83

In the previous week, DLocal had 1 more articles in the media than GoodRx. MarketBeat recorded 3 mentions for DLocal and 2 mentions for GoodRx. DLocal's average media sentiment score of 1.20 beat GoodRx's score of 0.63 indicating that DLocal is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DLocal	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DLocal beats GoodRx on 14 of the 16 factors compared between the two stocks.

How does GoodRx compare to Sezzle?

GoodRx (NASDAQ:GDRX) and Sezzle (NASDAQ:SEZL) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

63.8% of GoodRx shares are held by institutional investors. Comparatively, 2.0% of Sezzle shares are held by institutional investors. 5.9% of GoodRx shares are held by company insiders. Comparatively, 49.5% of Sezzle shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GoodRx has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Sezzle has a beta of 6.96, meaning that its share price is 596% more volatile than the broader market.

Sezzle has a net margin of 30.83% compared to GoodRx's net margin of 2.61%. Sezzle's return on equity of 87.46% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.61%	7.90%	3.23%
Sezzle	30.83%	87.46%	36.29%

Sezzle has lower revenue, but higher earnings than GoodRx. Sezzle is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.21	$30.44M	$0.06	46.83
Sezzle	$450.28M	8.45	$133.13M	$4.21	26.89

In the previous week, Sezzle had 8 more articles in the media than GoodRx. MarketBeat recorded 10 mentions for Sezzle and 2 mentions for GoodRx. Sezzle's average media sentiment score of 0.85 beat GoodRx's score of 0.63 indicating that Sezzle is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sezzle	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GoodRx currently has a consensus price target of $3.81, indicating a potential upside of 35.68%. Sezzle has a consensus price target of $123.00, indicating a potential upside of 8.67%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Sezzle.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Sezzle	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Sezzle beats GoodRx on 12 of the 17 factors compared between the two stocks.

How does GoodRx compare to Shift4 Payments?

GoodRx (NASDAQ:GDRX) and Shift4 Payments (NYSE:FOUR) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

GoodRx currently has a consensus price target of $3.81, suggesting a potential upside of 35.68%. Shift4 Payments has a consensus price target of $70.19, suggesting a potential upside of 74.73%. Given Shift4 Payments' stronger consensus rating and higher probable upside, analysts plainly believe Shift4 Payments is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Shift4 Payments	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, Shift4 Payments had 5 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for Shift4 Payments and 2 mentions for GoodRx. Shift4 Payments' average media sentiment score of 1.09 beat GoodRx's score of 0.63 indicating that Shift4 Payments is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shift4 Payments	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.8% of GoodRx shares are owned by institutional investors. Comparatively, 98.9% of Shift4 Payments shares are owned by institutional investors. 5.9% of GoodRx shares are owned by company insiders. Comparatively, 25.2% of Shift4 Payments shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GoodRx has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Shift4 Payments has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Shift4 Payments has a net margin of 2.63% compared to GoodRx's net margin of 2.61%. Shift4 Payments' return on equity of 33.55% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.61%	7.90%	3.23%
Shift4 Payments	2.63%	33.55%	5.01%

Shift4 Payments has higher revenue and earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than Shift4 Payments, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.21	$30.44M	$0.06	46.83
Shift4 Payments	$4.18B	0.76	$119M	$0.84	47.82

Summary

Shift4 Payments beats GoodRx on 14 of the 16 factors compared between the two stocks.

How does GoodRx compare to Life360?

GoodRx (NASDAQ:GDRX) and Life360 (NASDAQ:LIF) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, Life360 had 15 more articles in the media than GoodRx. MarketBeat recorded 17 mentions for Life360 and 2 mentions for GoodRx. GoodRx's average media sentiment score of 0.63 beat Life360's score of 0.48 indicating that GoodRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Life360	4 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GoodRx currently has a consensus target price of $3.81, indicating a potential upside of 35.68%. Life360 has a consensus target price of $63.94, indicating a potential upside of 38.24%. Given Life360's stronger consensus rating and higher probable upside, analysts plainly believe Life360 is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Life360	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Life360 has lower revenue, but higher earnings than GoodRx. Life360 is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.21	$30.44M	$0.06	46.83
Life360	$489.48M	7.66	$150.83M	$1.73	26.74

GoodRx has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Life360 has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

63.8% of GoodRx shares are held by institutional investors. Comparatively, 20.0% of Life360 shares are held by institutional investors. 5.9% of GoodRx shares are held by insiders. Comparatively, 6.8% of Life360 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Life360 has a net margin of 28.21% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat Life360's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.61%	7.90%	3.23%
Life360	28.21%	6.80%	3.65%

Summary

Life360 beats GoodRx on 11 of the 16 factors compared between the two stocks.

How does GoodRx compare to JOYY?

JOYY (NASDAQ:YY) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, GoodRx had 1 more articles in the media than JOYY. MarketBeat recorded 2 mentions for GoodRx and 1 mentions for JOYY. GoodRx's average media sentiment score of 0.63 beat JOYY's score of 0.53 indicating that GoodRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JOYY	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

JOYY has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

JOYY has higher revenue and earnings than GoodRx. JOYY is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JOYY	$2.24B	1.65	$301.82M	-$3.10	N/A
GoodRx	$796.85M	1.21	$30.44M	$0.06	46.83

36.8% of JOYY shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 43.0% of JOYY shares are held by insiders. Comparatively, 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

JOYY currently has a consensus target price of $66.00, indicating a potential downside of 3.94%. GoodRx has a consensus target price of $3.81, indicating a potential upside of 35.68%. Given GoodRx's higher possible upside, analysts plainly believe GoodRx is more favorable than JOYY.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JOYY	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

JOYY has a net margin of 9.02% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat JOYY's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JOYY	9.02%	4.64%	2.96%
GoodRx	2.61%	7.90%	3.23%

Summary

GoodRx beats JOYY on 10 of the 16 factors compared between the two stocks.

Get GoodRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDRX vs. The Competition

Export

Metric	GoodRx	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01B	$8.45B	$6.47B	$12.54B
Dividend Yield	N/A	1.79%	2.69%	5.22%
P/E Ratio	46.84	17.06	18.89	22.53
Price / Sales	1.21	19.03	520.79	112.26
Price / Cash	7.37	87.48	41.34	57.13
Price / Book	1.55	5.07	9.84	6.72
Net Income	$30.44M	$178.24M	$3.57B	$337.19M
7 Day Performance	-1.75%	-0.90%	-1.16%	0.48%
1 Month Performance	10.20%	3.75%	3.85%	5.07%
1 Year Performance	-28.68%	2.21%	27.40%	34.25%

GoodRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDRX GoodRx	3.5078 of 5 stars	$2.81 -4.7%	$3.81 +35.7%	-22.8%	$1.01B	$796.85M	46.84	950
DLO DLocal	4.9269 of 5 stars	$12.06 flat	$16.63 +37.9%	+10.2%	$3.56B	$1.09B	19.14	1,274	Positive News Insider Trade
SEZL Sezzle	3.7402 of 5 stars	$102.80 flat	$118.00 +14.8%	+5.3%	$3.46B	$450.28M	24.42	540	Analyst Forecast Gap Down
FOUR Shift4 Payments	4.9102 of 5 stars	$43.28 +0.1%	$71.38 +64.9%	-54.6%	$3.43B	$4.18B	51.52	6,300	Positive News Analyst Upgrade
LIF Life360	3.5043 of 5 stars	$40.22 flat	$63.94 +59.0%	-23.1%	$3.26B	$489.48M	23.25	600	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GoodRx (GDRX) Competitors